Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Holoclara

Holoclara Selects Eosinophilic Esophagitis as its Lead Indication for HC002, a First-in-Class Worm-Derived Therapy
From Holoclara
Via Business Wire
Holoclara Initiates Phase 1 Clinical Trial Evaluating Worm-Derived Therapeutic HC002 in Healthy Adults
From Holoclara
Via Business Wire
Holoclara Announces $16 Million Series A Financing to Advance a Breakthrough Class of Worm-Derived Therapies for Allergic and Autoimmune Disease
From Holoclara
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.